ER-Positive Breast Cancer in the Era of Precision Oncology

Hear from experts as they discuss genomics, resistance, and emerging drug targets.

Your gift is doubled through December 31.

Donate Now
Date
July 17, 2026

Seth Wander, MD, PhD, Mass General, and Elena Michaels, MD, Mass General and Dana-Farber Cancer Institute, discuss how genomic sequencing is reshaping the understanding and treatment of ER-positive breast cancer.

This session explores key molecular drivers of resistance, the role of tumor sequencing in identifying actionable alterations, and the emerging therapies and drug targets transforming treatment strategies across the disease continuum.

Speakers

Seth Wander, MD, PhD
Mass General
Elena Michaels, MD
Mass General and Dana-Farber Cancer Institute